A Two-Year Study to Assess the Efficacy, Safety and Tolerability of Taranabant, a Highly Selective CB1-R Inverse Agonist, in Obese Patients: 104-Week Results

被引：0
|
作者：
Aronne, Louis J.
Tonstad, Serena
Gantz, Ira
Erondu, Ngozi
Sieberts, Solveig
Molony, Cliona
Suryawanshi, Shailaja
Nayee, Jagriti
Levonas, Amy
Heymsfield, Steven
Kaufman, Keith
Amatruda, John
机构：
来源：
OBESITY | 2008年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S89 / S89
页数：1
相关论文
共 13 条
  • [1] A One-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant, a Highly Selective CB1-R Inverse Agonist, in Overweight and Obese Patients with Type 2 Diabetes: 36-Week Results
    Kipnes, Mark
    Hollander, Priscilla
    Gantz, Ira
    Seck, Thomas
    Eronda, Ngozi
    Shenta, Yue
    Lu, Kaifeng
    Suryawanshi, Shailaja
    Chou, Margaret
    Davies, Michael
    Heymsfield, Steven
    Kaufman, Keith
    OBESITY, 2008, 16 : S293 - S293
  • [2] A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results
    Moreno, M.
    Gantz, I.
    Erondu, N.
    Suryawanshi, S.
    Musser, B.
    Nayee, J.
    Johnson-Levonas, A. O.
    Heymsfield, S.
    Amatruda, J.
    CIRCULATION, 2008, 118 (12) : E415 - E415
  • [3] A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results
    Proietto, J.
    Gantz, I
    Carr, R. D.
    Erondu, N.
    Moreno, M.
    Suryawanshi, S.
    Musser, B.
    Nayee, J.
    Johnson-Levonas, A. O.
    Heymsfield, S.
    Amatruda, J.
    INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 : S22 - S22
  • [4] A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52 week results
    Gantz, Ira
    Erondu, Ngozi
    Suryawanshi, Shailaja
    Musser, Bret
    Nayee, Jagriti
    Johnson-Levonas, Amy O.
    Heymsfield, Steven
    Amatruda, John
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A326 - A327
  • [5] A TWO-YEAR STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF TARANABANT IN OBESE PATIENTS: 52 WEEK RESULTS
    Carr, R. D.
    Gantz, I.
    Erondu, N.
    Moreno, M.
    Suryawanshi, S.
    Musser, B.
    Nayee, J.
    Johnson-Levonas, A. O.
    Heymsfield, S.
    Amatruda, J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (01) : 12 - 12
  • [6] A One-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant, a Highly Selective CB1-R Inverse Agonist, in Overweight and Obese Patients with Type 2 Diabetes (T2DM): 52-Week Results
    Carr, Richard D.
    Heymsfield, Steven
    Suryawanshi, Shailaja
    Chou, Margaret Zeng
    Harp, Joyce B.
    Kaufman, Keith D.
    Amatruda, John M.
    Kipnes, Mark
    Hollander, Priscilla
    Fujioka, Ken
    Gantz, Ira
    Seck, Thomas
    Erondu, Ngozi
    Shentu, Yue
    Lu, Kaifeng
    OBESITY, 2009, 17 : S134 - S134
  • [7] Safety and Efficacy of Taranabant, a Highly Selective CB1-R Inverse Agonist, over One Year in Obese and Overweight Patients with Obesity-Related Co-Morbidities
    Proietto, Joseph
    Rissanen, Aila
    Harp, Joyce
    Erondu, Ngozi
    Yu, Qinfen
    Suryawanshi, Shailaja
    Jones, Mary Elizabeth
    Newcomb, Kathleen
    Heymsfield, Steven
    Kaufman, Keith
    Amatruda, John
    OBESITY, 2008, 16 : S63 - S63
  • [8] A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
    Kipnes, M. S.
    Hollander, P.
    Fujioka, K.
    Gantz, I.
    Seck, T.
    Erondu, N.
    Shentu, Y.
    Lu, K.
    Suryawanshi, S.
    Chou, M.
    Johnson-Levonas, A. O.
    Heymsfield, S. B.
    Shapiro, D.
    Kaufman, K. D.
    Amatruda, J. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (06): : 517 - 531
  • [9] A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
    L J Aronne
    S Tonstad
    M Moreno
    I Gantz
    N Erondu
    S Suryawanshi
    C Molony
    S Sieberts
    J Nayee
    A G Meehan
    D Shapiro
    S B Heymsfield
    K D Kaufman
    J M Amatruda
    International Journal of Obesity, 2010, 34 : 919 - 935
  • [10] A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study
    Aronne, L. J.
    Tonstad, S.
    Moreno, M.
    Gantz, I.
    Erondu, N.
    Suryawanshi, S.
    Molony, C.
    Sieberts, S.
    Nayee, J.
    Meehan, A. G.
    Shapiro, D.
    Heymsfield, S. B.
    Kaufman, K. D.
    Amatruda, J. M.
    INTERNATIONAL JOURNAL OF OBESITY, 2010, 34 (05) : 919 - 935
12